Journal
CANCER LETTERS
Volume 336, Issue 2, Pages 253-259Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.03.010
Keywords
DC vaccine; PD-L1; Immune checkpoints; Breast cancer
Categories
Funding
- 973 Project [2013CB530501]
- National Natural Science Foundation of China [30930085, 31200661, 81000912]
- Natural Science Foundation of Jiangsu Province, China [BK2012621]
- Suzhou Municipal Natural Science Foundation [SYS201106]
Ask authors/readers for more resources
Immune checkpoints, such as the PD-1/PD-L1 pathway, negatively interfere in the efficiency of dendritic cell (DC) vaccination in cancer immunotherapy. In this study, we demonstrated that the blockade of PD-L1 signaling could promote DC maturation, proliferation, and IL-12 secretion, augment DC primed T cell response and reverse tumor cell dampened T cell impairment. Blockade of PD-L1 signaling during DC vaccination showed better therapeutic effects than classic DC vaccination by preventing tumor growth and prolonging survival times in a breast tumor-bearing hu-SCID model. Taken together, suppressing immune checkpoints during DC vaccination might be a more efficient strategy for cancer therapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available